Compare with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PFIZER ALKEM LABORATORIES/
PFIZER
 
P/E (TTM) x - 32.7 - View Chart
P/BV x 6.7 5.5 121.9% View Chart
Dividend Yield % 0.6 0.6 104.3%  

Financials

 ALKEM LABORATORIES   PFIZER
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
PFIZER
Mar-18
ALKEM LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,5892,365 67.2%   
Low Rs1,2321,625 75.8%   
Sales per share (Unadj.) Rs417.5430.3 97.0%  
Earnings per share (Unadj.) Rs56.378.7 71.5%  
Cash flow per share (Unadj.) Rs64.793.2 69.4%  
Dividends per share (Unadj.) Rs12.7020.00 63.5%  
Dividend yield (eoy) %0.91.0 89.8%  
Book value per share (Unadj.) Rs292.9586.5 49.9%  
Shares outstanding (eoy) m119.5745.75 261.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.6 72.9%   
Avg P/E ratio x25.125.3 98.8%  
P/CF ratio (eoy) x21.821.4 101.8%  
Price / Book Value ratio x4.83.4 141.6%  
Dividend payout %22.625.4 88.8%   
Avg Mkt Cap Rs m168,65391,271 184.8%   
No. of employees `000NA2.6 0.0%   
Total wages/salary Rs m9,1713,143 291.8%   
Avg. sales/employee Rs ThNM7,484.8-  
Avg. wages/employee Rs ThNM1,195.0-  
Avg. net profit/employee Rs ThNM1,369.1-  
INCOME DATA
Net Sales Rs m49,91519,685 253.6%  
Other income Rs m1,6451,143 143.9%   
Total revenues Rs m51,56120,828 247.6%   
Gross profit Rs m8,4825,003 169.5%  
Depreciation Rs m1,006663 151.8%   
Interest Rs m6714 15,966.7%   
Profit before tax Rs m8,4515,479 154.2%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,878 85.5%   
Profit after tax Rs m6,7313,601 186.9%  
Gross profit margin %17.025.4 66.9%  
Effective tax rate %19.034.3 55.4%   
Net profit margin %13.518.3 73.7%  
BALANCE SHEET DATA
Current assets Rs m27,06224,167 112.0%   
Current liabilities Rs m15,3249,544 160.5%   
Net working cap to sales %23.574.3 31.7%  
Current ratio x1.82.5 69.7%  
Inventory Days Days6755 120.7%  
Debtors Days Days4129 143.8%  
Net fixed assets Rs m12,6109,514 132.5%   
Share capital Rs m239458 52.3%   
"Free" reserves Rs m34,49026,375 130.8%   
Net worth Rs m35,02726,832 130.5%   
Long term debt Rs m1,21225 4,846.4%   
Total assets Rs m54,38736,900 147.4%  
Interest coverage x13.61,305.5 1.0%   
Debt to equity ratio x00 3,712.6%  
Sales to assets ratio x0.90.5 172.0%   
Return on assets %13.69.8 139.3%  
Return on equity %19.213.4 143.2%  
Return on capital %24.920.4 121.7%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56322 29,300.4%   
Fx outflow Rs m3,0121,489 202.3%   
Net fx Rs m3,552-1,466 -242.2%   
CASH FLOW
From Operations Rs m7,2593,318 218.8%  
From Investments Rs m1,864-2,383 -78.2%  
From Financial Activity Rs m-9,273-1,104 840.3%  
Net Cashflow Rs m-150-169 89.0%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 33.1 7.5 441.3%  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 23.7 -  
Shareholders   68,381 85,207 80.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS